also known dacgrf short drug affinity complexgrowth hormonereleasing factor synthetic analogue growth hormonereleasing hormone ghrh also known growth hormonereleasing factor grf growth hormone secretagogue ghs developed conjuchem modified form ghrh improved pharmacokinetics especially regard markedly increases plasma growth hormone gh insulinlike growth factor levels animals single injection human subjects increases plasma gh levels days longer plasma levels drug estimated halflife days multiple doses levels found remain elevated humans shown extend halflife bioavailability growthhormonereleasing hormone stimulate insulinlike growth factor secretion increases halflife acting agents investigation treatment lipodystrophy growth hormone deficiency reached phase ii clinical trials discontinued upon death one trial attending physician trial believed likely explanation incident patient asymptomatic coronary artery disease plaque rupture occlusion occurrence unrelated treatment research terminated nonetheless found grey market use bodybuilding purposes countries netherlands illicit